Citamax 50/500 mg
Sitagliptin Phosphate 62.04mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea Prime Pharmaceutical Co., Ltd.
MFDS item code 201503229 · Approved 2015.05.27
This product's status changed to Expired on 2025.05.27. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in type 2 diabetes mellitus
This medication contains sitagliptin and metformin and is used to help manage blood sugar levels in patients with type 2 diabetes. When taken alongside dietary and exercise therapies, it can help effectively manage blood sugar levels. Therefore, it is beneficial for those experiencing difficulties in managing blood sugar.
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with food. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this medicine should be based on the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no previous experience of antidiabetic drug therapy who cannot achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose is one 50/500 mg tablet twice daily. The dose may be increased to one 50/1000 mg tablet twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Patients Who Must Not Use This Medicine). 2. Patients receiving metformin: - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this medicine is a total daily dose of sitagliptin 50 mg twice daily (total daily dose 100 mg) and the current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial dose of metformin should take the patient's blood glucose level and current dose into consideration. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this medicine. Any change in the treatment regimen for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used, with the following dosage adjustment, in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or glomerular filtration rate [eGFR] ≥ 45 and < 60 mL/min/1.73m2), who have no other conditions that may increase the risk of lactic acidosis. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment Because this medicine contains metformin, it should not be administered to patients with hepatic impairment (see Precautions for Use, 2. Patients Who Must Not Use This Medicine).
This medication is composed of two ingredients, sitagliptin and metformin, and is primarily used to assist with blood sugar control in patients with type 2 diabetes. During treatment with this medication, severe allergic reactions may occur. If you experience symptoms such as skin rashes, difficulty breathing, or swelling of the lips or face, you must immediately stop taking the medication and visit a hospital. Acute pancreatitis, a severe inflammation of the pancreas, may occur; sudden abdominal pain, nausea, or vomiting should prompt immediate consultation with a doctor. Patients with poor kidney function, dehydration, severe infections, or heart failure should not use this medication, and particularly those with impaired kidney function should avoid taking it. Prior to receiving tests involving iodine contrast agents, this medication should be temporarily discontinued, and it should only be resumed after confirming normal kidney function post-test. It is safer for women who are pregnant or breastfeeding to avoid taking this medication. This medication can cause hypoglycemia, so caution is necessary if meals are skipped, irregular eating habits are followed, or excessive exercise is performed. Additionally, while taking this medication, you should have your liver and kidney functions checked regularly to ensure there are no abnormalities. Alcohol can be dangerous when taken with this medication, so avoiding alcohol consumption is advisable. Patients scheduled for surgery should stop taking this medication 48 hours before surgery, and only resume it once recovering kidney function is confirmed after the procedure. During treatment with this medication, gastrointestinal disturbances such as diarrhea, headache, nausea, vomiting, or abdominal discomfort may occur. If severe joint pain or skin blisters develop, you should immediately consult a doctor. The risk of hypoglycemia can be increased when this medication is combined with other glucose-lowering drugs or insulin, so dosage adjustments may be needed if necessary. Elderly patients are at increased risk of deteriorating kidney function, so extra caution is needed when taking this medication, and regular kidney function tests are recommended. In the case of overdose, seek medical attention immediately for appropriate treatment, and the medication can be removed through dialysis. Patients taking this medication should fully understand the potential benefits and risks, and regularly monitor their blood sugar and kidney functions to manage their health status.
anaphylaxis
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container that does not allow air to pass through, preferably at a temperature between 1 and 30 degrees Celsius. Proper storage will help maintain the drug's effectiveness for a longer period.
Bright pink oval film-coated tablet
30 tablets/box [10 tablets/PTP x 3]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Sitagliptin Phosphate 62.04mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea Prime Pharmaceutical Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Jongkun Dang Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationMetformin Hydrochloride 500mg · Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication · Combination
Jong Kun Dang Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication · Combination
JongKeunDang Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
Sitagliptin Phosphate 62.04mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Yuyu Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.